Intravenous immunoglobulin (IVIG) attenuates antibody binding in acute haemorrhagic immunopneumonitis in a rat model of complement-dependent lung injury
- 1 July 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 121 (1) , 139-145
- https://doi.org/10.1046/j.1365-2249.2000.01252.x
Abstract
Administration of rabbit anti-rat lung serum (PNTS) to rats produces a fulminant haemorrhagic pneumonitis sensitive to the availability of complement. The present experiments were undertaken to assess whether a high dose of IVIG can affect the development of this kind of cytotoxic reaction. The experimental design included groups of Wistar rats pretreated intravenously with physiologic saline, IVIG or a preparation of human F(ab′)2 fragments. One hour later the animals were challenged with either saline or PNTS. At 30 min after challenge, blood was collected and the lungs were removed. Pulmonary damage was evaluated by light microscopy; C3 deposits and the binding of immunoglobulins to the alveolar septa were assayed by immunofluorescence. The serum complement activity of the classical and alternative pathways was estimated by a kinetic technique. Pretreatment with IVIG decreased binding of rabbit anti-lung antibodies to alveolar septa and prevented the deposition of C3. These results indicate that pretreatment with IVIG inhibits the binding of the pathogenic antibody to lung tissue. Human IgG binding was not detected in any animal. The protection against lung injury afforded by pretreatment with IVIG, in contrast to the pneumotoxic effect of PNTS observed in control animals, was evident despite the administration of F(ab′)2 to the rats. Since pretreatment with F(ab′)2 failed to prevent the acute lung lesion, our results indicate that the attenuation afforded by IVIG in this model of complement-dependent tissue injury seems to be related to the integrity of the IgG molecule.Keywords
This publication has 48 references indexed in Scilit:
- High-Dose Intravenous Immunoglobulin Treatment Activates Complement In VivoScandinavian Journal of Immunology, 1998
- Beneficial effects of systemic immunoglobulin in experimental membranous nephropathyKidney International, 1996
- Inhibition of complement activation by intravenous immunoglobulinsArthritis & Rheumatism, 1995
- Beneficial effect of human therapeutic intravenous immunoglobulins (IVIg) in mercuric-chloride-induced autoimmune disease of Brown-Norway ratsClinical and Experimental Immunology, 1991
- Serum Haemolytic Classical and Alternative Pathways of Complement in Infancy: Age‐Related ChangesActa Paediatrica, 1990
- Improvement of Histological and Immunological Change in Steroid and Immunosuppressive Drug-Resistant Lupus nephritis by High-Dose Intravenous Gamma GlobulinNephron, 1989
- Intravenous and standard immune serum globulin preparations interfere with uptake of 125I-C3 onto sensitized erythrocytes and inhibit hemolytic complement activityClinical Immunology and Immunopathology, 1985
- The interaction of immune serum globulin and immune globulin intravenous with complementMolecular Immunology, 1983
- HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOODThe Lancet, 1981
- A SPECIFIC INACTIVATOR OF MAMMALIAN C'4 ISOLATED FROM NURSE SHARK (Ginglymostoma cirratum) SERUMThe Journal of Experimental Medicine, 1969